Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
SHELTON, CT / / September 28, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo E…
NanoViricides said the clinical trial of oral drug NV-387 to treat Ebola has started enrollment and dosing of patients.
NanoViricides (NNVC) said its Phase II clinical trial of NV-387 oral gummies to treat the current Bundibugyo Ebola outbreak has been registered in the Pan African Clinical Trials Database and is ready to go.
NanoViricides, Inc. (NYSE: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bund